Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2021 Aug 4;20(10):2026–2034. doi: 10.1158/1535-7163.MCT-20-1112

Figure 2. MAPK-targeted therapy increases PD-L1 expression in cells comprising the PDAC tumor microenvironment.

Figure 2.

A. Transferrin receptor (TfR) expression decreases upon inhibition of KPC CAFs with ERK inhibitor SCH, and MEK inhibitor trametinib. MAPK inhibition (drugs against ERK and MEK) show a significant increase in PD-L1 expression on CAFs. B. TfR expression decreases upon inhibition of plated KPC cells with ERK inhibitor SCH, and MEK inhibitor trametinib. MAPK inhibition (drugs against ERK and MEK) show a significant increase in PD-L1 expression in KPC cells.